A sweeping U.S. Customs and Border Protection rule set to take effect October 22 could upend the Canadian pharmacy lifeline that millions of Americans rely on for affordable medications. The rule suspends the longstanding "de minimis" exemption — which previously allowed shipments valued under $800 to pass through customs with minimal hassle — and now requires a licensed customs broker and a financial bond guarantee for international mail, including prescription drugs. While the rule targets all international mail to curb illegal drug imports, patient advocates warn the real-world fallout will hit the most vulnerable hardest.

An estimated 2.3 million Americans purchase prescription drugs from abroad, with the most common buyers being seniors, uninsured individuals, and lower-income patients. The price differences are stark: apixaban (Eliquis), for example, costs as little as 70 cents per tablet from an international pharmacy vs. $5.53 at the lowest U.S. price. Some patients have already seen costs spike due to earlier tariffs on Canada, with one patient reporting her asthma medication jumped from $151 to $273.

By the Numbers

• ~2.3 million Americans buy prescription drugs from abroad (2020 JAMA Network Open study)
• Apixaban (Eliquis): 70¢/tablet internationally vs. $5.53 in the U.S.
• Empagliflozin (Jardiance): $1.08/tablet internationally vs. $11.21 in the U.S.
• Rivaroxaban (Xarelto): 81¢/tablet internationally vs. $19.56 in the U.S.
• U.S. prescription drug prices fell 3.1% year-over-year — the steepest drop since 1963

Why it matters: For patients who can't afford U.S. drug prices, Canadian pharmacies aren't a convenience — they're a lifeline. If the rule isn't paused or revised, clinicians may face patients rationing or skipping critical medications for chronic conditions like diabetes, heart disease, and asthma. Physicians should proactively discuss therapeutic alternatives, patient assistance programs, and drug coupons with affected patients.